CAPR

Capricor is a clinical-stage biotech whose entire equity story rests on one asset: Deramiocel, a cardiosphere-derived cell therapy for Duchenne muscular dystrophy, with a BLA now under FDA review and a PDUFA target action date of August 22, 2026. The MD&A is explicit that the company 'currently has no products approved for commercial sale' and that its ability to ever generate product revenue 'will depend on the successful development, regulatory approval and commercialization of Deramiocel.' That makes this a binary event stock, not a fundamentals story — and roughly two months from the catalyst, today's 10% drop reflects exactly that nerviness.

The numbers underline both the strength and the fragility. FY2025 revenue went to $0.00 (from $22.3M in FY2024, a -100% collapse as prior collaboration revenue rolled off), while the net loss widened to -$105M from -$40.5M and R&D climbed 69% to $84.5M as the company prepared for review and potential commercialization. ROE is -34.4%. The offset is a genuinely clean balance sheet: cash jumped to $288M (up from ~$11M), total liabilities are just $50.2M against $306M of equity (0.16x liabilities/equity), and current assets of $323M dwarf $35.8M of current liabilities. Against ~$70M operating cash burn, that is roughly two years of runway — Capricor can fund itself through the FDA decision and an initial launch without an immediate, dilutive raise, though shares already grew 25.9% in the year.